Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 13/20 | 0.71 |
| ▸ | GRM5 | P41594 | 11/20 | 0.60 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888969 | 0.90 | GRM1 (0.72) | GRM1GRM5DRD2DRD4DRD3 | |
| SCHEMBL2891168 | 0.87 | GRM1 (0.72) | GRM1GRM5FLT3ALDH1A1SMN1; SMN2 | |
| SCHEMBL2893262 | 0.86 | GRM1 (0.73) | GRM1GRM5DRD2DRD4DRD3 | |
| SCHEMBL2891855 | 0.83 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL2890987 | 0.82 | GRM1 (0.71) | GRM1GRM5DRD2DRD4DRD3 | |
| SCHEMBL2892949 | 0.82 | GRM1 (0.51) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL28761564 | 0.81 | GRM1 (0.74) | GRM1GRM5ALDH1A1 | |
| SCHEMBL2893523 | 0.80 | GRM1 (0.53) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2885105 | 0.78 | GRM1 (0.73) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL27666676 | 0.78 | GRM1 (0.74) | GRM1GRM5FLT3GSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1980901-A | Biaryl derivatives | BANYU PHARMA CO LTD (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | GRM1 1/4885GRM5 26/4885FLT3 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.